Orion Oyj

ORNAV

Equity

ISIN FI0009014369 / Valor 2553360

NASDAQ Helsinki Ltd, Equities (2024-09-17)

EUR 46.25-0.86%

Orion Oyj
UMushroom community rating:

0.00 0 votes No rating yet

NegativeNeutralPositive

About company

Orion Oyj is a pharmaceutical company that places a strong emphasis on partnerships and networking throughout its value chain. The company collaborates with other organizations in various areas such as research and development, manufacturing, and marketing of products on a global scale. This approach allows Orion to leverage the expertise and resources of its partners to enhance its operations and expand its reach in the pharmaceutical industry.

Summarized from source with an LLMView SourceSector: Healthcare

Net Sales Growth

Orion Oyj reported net sales of EUR 636.7 million for the first half of 2024, reflecting a 12.2% increase compared to EUR 567.5 million in the same period of 2023. This growth was driven by strong performance in key product lines, including Nubeqa® and Easyhaler®.

Operating Profit Increase

For the first half of 2024, Orion Oyj's operating profit rose to EUR 121.8 million, marking a 19.5% increase from EUR 102.0 million in the first half of 2023. The increase in operating profit was attributed to higher sales and effective cost management across the company's business divisions.

Basic Earnings Per Share

Orion Oyj's basic earnings per share for the first half of 2024 were EUR 0.68, up 19.2% from EUR 0.57 in the same period of the previous year. This improvement in earnings per share reflects the company's robust financial performance and profitability.

Cash Flow from Operating Activities

Cash flow from operating activities per share for Orion Oyj in the first half of 2024 was EUR 0.98, a significant increase compared to EUR 0.27 in the first half of 2023. This substantial rise indicates improved operational efficiency and cash generation capabilities.

Upgraded Financial Outlook

Following the strong performance in the first half of 2024, Orion Oyj upgraded its financial outlook for the full year. The company now estimates net sales to be between EUR 1,440 million and EUR 1,480 million, and operating profit to range from EUR 350 million to EUR 380 million, up from the previous estimates of EUR 1,340 million to EUR 1,410 million in net sales and EUR 280 million to EUR 310 million in operating profit.

Summarized from source with an LLMView Source

Key figures

25.9%1Y

34.3%3Y

42.5%5Y

Performance

24.2%1Y

29.3%3Y

29.5%5Y

Volatility